Identification of novel ARF binding proteins by two-hybrid screening

Cell Cycle

Volumn 5, Issue 6, 2006, Pages 641-646

  Van Tompkins, ^a   Hagen, Jussara ^a   Zediak, Valerie P ^a,b   Quelle, Dawn E ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ARF; Mdm2; p53; Yeast two hybrid screen

Indexed keywords

ARF PROTEIN; BINDING PROTEIN;

ARTICLE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TWO HYBRID SYSTEM;

EID: 33645283602     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83:993-1000.
2. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf. Progress and puzzles. Curr Op Gen Dev 2003; 13:77-83.
3. Pomerantz J, Schreiberagus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordoncardo C, DePinho RA. The INK4a tumor suppressor gene product, p19(ARF), interacts with mdm2 and neutralizes mdm2s inhibition of p53. Cell 1998; 92:713-23.
4. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34.
5. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17:5001-14.
6. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003; 1:993-1000.
7. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005; 121:1071-83.
8. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. p53-independent functions of the p19ARF tumor suppressor. Genes Dev 2000; 14:2358-65.
9. 2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene 2003; 22:1822-35.
10. Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ. p19(Arf) suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. Plos Biol 2004; 2:1138-49.
11. Hasan M, Yaguchi T, Sugihara T, Kumar PKR, Taira K, Reddel RR, Kaul SC, Wadhwa R. CARF is a novel protein that cooperates with mouse p19ARF (Human p14ARF) in activating p53. J Biol Chem 2002; 277:37765.
12. 1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways. Mol Cancer Res 2003; 1:195-206.
13. Rizos H, Diefenbach E, Badhwar P, Woodruff S, Becker TM, Rooney RJ, Kefford RF. Association of p14(ARF) with the p120(E4F) transcriptional repressor enhances cell cycle inhibition. J Biol Chem 2003; 278:4981-9.
14. Pollice A, Nasti V, Ronca R, Vivo M, Iacono ML, Calogero R, Calabro V, La Mantia G. Functional and physical interaction of the human ARF tumor suppressor with Tat-binding protein-1. J Biol Chem 2004; 279:6345-53.
15. Jackson MW, lindstrom MS, Berberich SJ. MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. J Biol Chem 2001; 276:25336-41.
16. Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, Quelle FW, Quelle DE. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 2005; 25:1258-71.
17. Cleveland JL, Sherr CJ. Antagonism of Myc functions by Arf. Cancer Cell 2004; 6:309-11.
18. Eymin B, Karayan L, Seite P, Brambilla C, Brambilla E, Larsen CJ, Gazzeri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 2001; 20:1033-41.
19. Martelli F, Hamilton T, Silver DP, et al. p19ARF targets certain E2F species for degradation. Proc Natl Acad Sci USA 2001; 98:4455-60.
20. Mason SL, Loughran O, La Thangue NB. p14(ARF) regulates E2F activity. Oncogene 2002; 21:4220-30.
21. Datta A, Nag A, Raychaudhuri P. Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF. Mol Cell Biol 2002; 22:8398-408.
22. 1 arrest function of ARF. Mol Cell Biol 2005; 25:8024-36.
23. Fatyol K, Szalay AA. The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits HIF-1-mediated transcription. J Biol Chem 2001; 276:28421-9.
24. Itahana K, Bhat KP, Jin AW, Itahana Y, Hawke D, Kobayashi R, Zhang YP. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003; 12:1151-64.
25. Brady SN, Yu Y, Maggi Jr LB, Weber JD. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol 2004; 24:9327-38.
26. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the ARF tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004; 24:985-96.
27. McKeller RN, Fowler JL, Cunningham JJ, Warner N, Smeyne RJ, Zindy F, Skapek SX. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci USA 2002; 99:3848-53.
28. Hirano M, Kaneko S, Yamashita T, Luo H, Qin W, Shirota Y, Nomura T, Kobayashi K, Murakami S. Direct interaction between nucleolin and hepatitis C virus NS5B. J Biol Chem 2003; 278:5109-15.
29. Quelle DE, Cheng MG, Ashmun RA, Sherr CJ. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16(INK4A) but not by the alternative reading frame protein p19(ARF). Proc Natl Acad Sci USA 1997; 94:669-73.
30. Hoshino S, Imai M, Mizutani M, Kikuchi Y, Hanaoka F, Ui M, Katada T. Molecular cloning of a novel member of the eukaryotic polypeptide chain-releasing factors (eRF). J Biol Chem 1998; 273:22254-9.
31. Tompkins V, Hagen J, Frazier AA, Boyd J, di Tommaso A, Ladeveze V, Quelle DE. Identification of NIAM, a nuclear interactor of ARF and Mdm2 that potently inhibits cell proliferation. Mauscript submitted.
32. Henry MK, Lynch JT, Eapen AK, Quelle FW. DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway. Blood 2001; 98:834-41.
33. Weber JD, Kuo ML, Bothner B, DiGiammarino EL, Kriwacki RW, Roussel, MF, Sherr CJ. Cooperative signals governing ARF-Mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol 2000; 20:2517-28.
34. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19(ARF). Cell 1997; 91:649-59.
35. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987; 7:2745-52.
36. Korgaonkar C, Zhao L, Modestou M, Quelle DE. ARF function does not require p53 stabilization or Mdm2 relocalization. Mol Cell Biol 2002; 22:196-206.
37. James GL, Goldstein JL, Pathak RK, Anderson RGW, Brown MS. PXF, a prenylated protein of peroxisomes. J Biol Chem 1994; 269:14182-90.
38. Sugihata T, Kaul SC, Kato JY, Reddel RR, Nomura H, Wadhwa R. Pex19p dampens the p19ARF-p53-p21WAF1 tumor suppressor pathway. J Biol Chem 2001; 276:18649-52.
39. Vivo M, Calogero RA, Sansone F, Calabro V, Parisi T, Borrelli L, Saviozzi S, La Mantia G. The human tumor suppressor ARF interacts with Spinophilin/Neurabin II, a type 1 protein-phosphatase-binding protein. J Biol Chem 2001; 276:14161-9.
40. Moore SK, Kozak C, Robinson EA, Ullrich SJ, Appella E. Cloning and nucleotide-sequence of the murine Hsp84 cDNA and chromosome assignment of related sequences. Gene 1987; 56:29-40.
41. Zhang A, Yeung PL, Li CW, Tsai SC, Dinh GK, Wu X, Li H, Chen JD. Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators. J Biol Chem 2004; 279:33799-805.
42. Saotome Y, Winter CG, Hirsh D. A widely expressed novel C2H2 zinc-finger protein with multiple consensus phosphorylation sites is conserved in mouse and man. Gene 1995; 152:233-8.
43. Wadhwa R, Sugihara T, Hasan M, Taira K, Reddel RR, Kaul SC. A major functional difference between the mouse and human ARF tumor suppressor proteins. J Biol Chem 2002; 277:36665.
44. Ginisty H, Sicard H, Roger B, Bouvet P. Structure and functions of nucleolin. J Cell Sci 1999; 112:761-72.
45. Sugimoto M, Kuo ML, Roussel MF, Sherr CJ. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 2003; 11:415-24.
46. 1-to-S transition encodes a protein containing an A-kinase target site and GTPase domain. EMBO J 1988; 7:1175-82.
47. Hoshino S, Miyazawa H, Enomoto T, Hanaoka F, Kikuchi Y, Kikuchi A, Ui M. A human homologue of the yeast GST1 gene codes for a GTP-binding protein and is expressed in a proliferation-dependent manner in mammalian cells. EMBO J 1989; 8:3807-14.
48. Hoshino S, Imai M, Kobayashi T, Uchida N, Katada T. The eukaryotic polypeptide chain releasing factor (eRF3/GSPT) carrying the translation termination signal to the 3′-poly(A) tail of mRNA. J Biol Chem 1999; 274:16677-80.
49. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Ann Rev Pharm Toxicol 2001; 41:723-49.
50. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF. Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol Care 2005; 43:225-36.
51. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM, Santoro M. Osteopontin is overexpresscd in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrin Metab 2005; 90:5270-8.
52. Behrends U, Schneider I, Rossler S, Frauenknecht H, Golbeck A, Lechner B, Eigenstetter G, Zobywalski C, Muller-Weihrich S, Graubner U, Schmid I, Sackerer D, Spath M, Goetz C, Prantl F, Asmuss HP, Bise K, Mautner J. Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries. Intl J Cancer 2003; 106:244-51.
53. Powell JA, Gardner AE, Bais AJ, Hinze SJ, Baker E, Whitmore S, Crawford J, Kochetkova M, Spendlove HE, Doggett NA, Sutherland GR, Callen DF, Kremmidiotis G. Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes. Genomics 2002; 80:303-10.
54. Rocha S, Campbell KJ, Perkins ND. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol Cell 2003; 12:15-25.
55. Muller L, Schaupp A, Walerych D, Wegele H, Buchner J. Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures. J Biol Chem 2004; 279:48846-54.
56. Walerych D, Kudla G, Gutkowska M, Wawrzynow B, Muller L, King FW, Helwak A, Boros J, Zylicz A, Zylicz M. Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem 2004; 279:48836-45.
57. Esser C, Scheffner M, Hohfeld J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 2005; 280:27443-8.
58. Jascur T, Brickner H, Salles-Passador I, Barbier V, El Khissiin A, Smith B, Fotedar R, Fotedar A. Regulation of p21(WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein. Mol Cell 2005; 17:237-49.
59. Pott U, Thiesen HJ, Colello RJ, Schwab ME. A new cys(2)/his(2) zinc-finger gene, rkr2, is expressed in differentiated rat oligodendrocytes and encodes protein with a functional repressor domain. J Neurochem 1995; 65:1955-66.
60. Lovas G, Li W, Pott U, Verga T, Hudson LD. Expression of the Kruppel-type zinc finger protein rKr2 in the developing nervous system. Glia 2001; 34:110-20.
61. Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O, Mori Y, Raychaudhuri P. Myc-ARF (Alternate Reading Frame) interaction inhibits the functions of Myc. J Biol Chem 2004; 279:36698-707.
62. Qi Y, Gregory MA, Li ZL, Brousal JP, West K, Hann SR. p19(ARF) directly and differentially controls the functions of c-Myc independently of p53. Nature 2004; 431:712-7.
63. Kalinichenko W, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, Dennewitz MB, Shin B, Datta A, Raychaudhuri P, Costa RH. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 2004; 18:830-50.
64. Calabro V, Mansueto G, Santoro R, Gentilella A, Pollice A, Ghioni P, Guerrini L, La Mantia G. Inhibition of p63 transcriptional activity by p14ARF: Functional and physical link between human ARF tumor suppressor and a member of the p53 family. Mol Cell Biol 2004; 24:8529-40.
65. Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF, Sherr CJ. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci USA 2003; 100:15930-5.
66. Unoki M, Okutsu J, Nakamura Y. Identification of a novel human gene, ZFP91, involved in acute myelogenous leukemia. Intl J Onc 2003; 22:1217-23.
67. Linggi B, Muller-Tidow C, van de Locht L, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Jansen JH, Hiebert SW. The t(8; 21) fusion protein, AML-1/ETO, specifically represses transcription of the p14(ARF) tumor suppressor in acute myeloid leukemias. Blood 2001; 98:834A.
68. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13:2658-69.
69. Modestou M, Puig-Antich V, Korgaonkar C, Eapen A, Quelle DE. The ARF tumor suppressor inhibits growth through p21-dependent and p21-independent pathways. Cancer Res 2001; 61:3145-50.
70. Groth A, Weber JD, Willumsen BM, Sherr CJ, Roussel MF. Oncogenic ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking p21Cip1 and p27Kip1 without activating cyclin D-dependent kinases. J Biol Chem 2000; 275:27473-80.